Opiant Pharmaceuticals
0
0
+€0.00+0% 00:00 Today
Statistics
Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
About
Opiant Pharmaceuticals, Inc. engages in the development of pharmaceutical solutions for common addictions and related disorders. The company is headquartered in Santa Monica, California and currently employs 3 full-time employees. The firm develops pharmacological treatments for substance use, addictive and eating disorders. The firm has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA). The firm's pipeline of product candidates includes a treatment for Binge Eating Disorder (BED), a treatment for Bulimia Nervosa (BN), a treatment for Cocaine Use Disorder (CocUD) and a heroin vaccine. The firm also is focused on other treatment opportunities.
Show More
CEO
Employees
30
Country
United States
ISIN
US6837501039
Listings
0 Comments
Share your thoughts
FAQs
What is Opiant Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Opiant Pharmaceuticals stocks are traded under the ticker 8OP.STU.
How many employees does Opiant Pharmaceuticals have?▼
As of November 2, 2026, the company has 30 employees.
In which sector is Opiant Pharmaceuticals located?▼
Opiant Pharmaceuticals operates in the Manufacturing sector.
When did Opiant Pharmaceuticals complete a stock split?▼
The last stock split for Opiant Pharmaceuticals was on August 20, 2009 with a ratio of 19:1.